{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T20:51:57Z","timestamp":1778878317781,"version":"3.51.4"},"reference-count":26,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCEH","J Clin Exp Hematopathol"],"published-print":{"date-parts":[[2023]]},"DOI":"10.3960\/jslrt.23005","type":"journal-article","created":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T22:12:50Z","timestamp":1687903970000},"page":"108-120","source":"Crossref","is-referenced-by-count":3,"title":["Japanese subgroup analysis in the Asian phase II study of                    darinaparsin in patients with relapsed or refractory peripheral T-cell                    lymphoma"],"prefix":"10.3960","volume":"63","author":[{"given":"Eiju","family":"Negoro","sequence":"first","affiliation":[{"name":"University of Fukui Hospital, Fukui, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Yamauchi","sequence":"additional","affiliation":[{"name":"University of Fukui Hospital, Fukui, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriko","family":"Fukuhara","sequence":"additional","affiliation":[{"name":"Tohoku University Hospital, Sendai, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhito","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Aichi Cancer Center, Nagoya, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiki","family":"Uchida","sequence":"additional","affiliation":[{"name":"Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital,                            Nagoya, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Izutsu","sequence":"additional","affiliation":[{"name":"National Cancer Center Hospital, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dai","family":"Maruyama","sequence":"additional","affiliation":[{"name":"National Cancer Center Hospital, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhito","family":"Terui","sequence":"additional","affiliation":[{"name":"The Cancer Institute Hospital of Japanese Foundation for Cancer                            Research, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideaki","family":"Nakajima","sequence":"additional","affiliation":[{"name":"Yokohama City University Hospital, Yokohama, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyoshi","family":"Ando","sequence":"additional","affiliation":[{"name":"Tokai University Hospital, Isehara, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youko","family":"Suehiro","sequence":"additional","affiliation":[{"name":"National Hospital Organization Kyushu Cancer Center, Fukuoka,                            Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilseung","family":"Choi","sequence":"additional","affiliation":[{"name":"National Hospital Organization Kyushu Cancer Center, Fukuoka,                            Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhiro","family":"Kanemura","sequence":"additional","affiliation":[{"name":"Gifu University Hospital, Gifu, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhiko","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Gifu University Hospital, Gifu, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Go","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Toranomon Hospital, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinobu","family":"Maeda","sequence":"additional","affiliation":[{"name":"Okayama University Hospital, Okayama, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirohiko","family":"Shibayama","sequence":"additional","affiliation":[{"name":"Osaka University Hospital, Osaka, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumiko","family":"Nagahama","sequence":"additional","affiliation":[{"name":"Solasia Pharma K.K., Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Sonehara","sequence":"additional","affiliation":[{"name":"Solasia Pharma K.K., Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirokazu","family":"Nagai","sequence":"additional","affiliation":[{"name":"National Hospital Organization Nagoya Medical Center, Nagoya,                            Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hwei-Fang","family":"Tien","sequence":"additional","affiliation":[{"name":"National Taiwan University Hospital, Taipei, Taiwan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yok-Lam","family":"Kwong","sequence":"additional","affiliation":[{"name":"Queen Mary Hospital, Hong Kong,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Won-Seog","family":"Kim","sequence":"additional","affiliation":[{"name":"Samsung Medical Center, Sungkyunkwan University School of                            Medicine, Seoul, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kensei","family":"Tobinai","sequence":"additional","affiliation":[{"name":"National Cancer Center Hospital, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2349","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Aoki                            R,                                Karube                            K,                                Sugita                            Y                    <i>et al.<\/i> Distribution of malignant lymphoma in Japan: analysis of                    2260 cases, 2001-2006. Pathol Int. 2008; 58: 174-182.","DOI":"10.1111\/j.1440-1827.2007.02207.x"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Chihara                            D,                                Ito                            H,                                Matsuda                            T                    <i>et al.<\/i> Differences in incidence and trends of haematological                    malignancies in Japan and the United States. Br J Haematol. 2014; 164:                    536-545.","DOI":"10.1111\/bjh.12659"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Alaggio R, Amador C, Anagnostopoulos I, et                    al. The 5th edition of the World Health Organization classification of                    haematolymphoid tumours: Lymphoid neoplasms. Leukemia. 2022; 36:                    1720-1748.","DOI":"10.1038\/s41375-022-01620-2"},{"key":"4","unstructured":"4 Gisselbrecht                            C,                                Gaulard                            P,                                Lepage                            E                    <i>et al.<\/i> Prognostic significance of T-cell phenotype in                    aggressive non-Hodgkin\u2019s lymphomas. Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte                    (GELA). Blood. 1998; 92: 76-82."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Puig                            N,                                Wang                            L,                                Seshadri                            T                    <i>et al.<\/i> Treatment response and overall outcome of patients with                    relapsed and refractory peripheral T-cell lymphoma compared to diffuse large                    B-cell lymphoma. Leuk Lymphoma. 2013; 54: 507-513.","DOI":"10.3109\/10428194.2012.719615"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Skamene                            T,                                Crump                            M,                                Savage                            KJ                    <i>et al.<\/i> Salvage chemotherapy and autologous stem cell                    transplantation for peripheral T-cell lymphoma: a subset analysis of the                    Canadian Cancer Trials Group LY.12 randomized phase 3 study. Leuk Lymphoma.                    2017; 58: 2319-2327.","DOI":"10.1080\/10428194.2017.1312379"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Mak                            V,                                Hamm                            J,                                Chhanabhai                            M                    <i>et al.<\/i> Survival of patients with peripheral T-cell lymphoma                    after first relapse or progression: spectrum of disease and rare long-term                    survivors. J Clin Oncol. 2013; 31: 1970-1976.","DOI":"10.1200\/JCO.2012.44.7524"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Chihara                            D,                                Fanale                            MA,                                Miranda                            RN                    <i>et al.<\/i> The survival outcome of patients with                    relapsed\/refractory peripheral T-cell lymphoma-not otherwise specified and                    angioimmunoblastic T-cell lymphoma. Br J Haematol. 2017; 176:                    750-758.","DOI":"10.1111\/bjh.14477"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Mann                            KK,                                Wallner                            B,                                Lossos                            IS,                                Miller                            WH                            Jr. Darinaparsin: a novel                    organic arsenical with promising anticancer activity. Expert Opin Investig                    Drugs. 2009; 18: 1727-1734.","DOI":"10.1517\/13543780903282759"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Garnier                            N,                                Redstone                            GGJ,                                Dahabieh                            MS                    <i>et al.<\/i> The novel arsenical darinaparsin is transported by                    cystine importing systems. Mol Pharmacol. 2014; 85: 576-585.","DOI":"10.1124\/mol.113.089433"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Yuan                            B,                                Kikuchi                            H,                                Li                            J                    <i>et al.<\/i> Cytotoxic Effects of Darinaparsin, a Novel Organic                    Arsenical, against Human Leukemia Cells. Int J Mol Sci. 2023; 24:                    2282.","DOI":"10.3390\/ijms24032282"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Kim WS, Fukuhara N, Yoon DH, <i>et                        al.<\/i> Darinaparsin in Patients with Relapsed or Refractory Peripheral                    T-Cell Lymphoma: Results of an Asian Phase 2 Study. Blood Adv. 2023;                    bloodadvances.2022008615; Online ahead of print.","DOI":"10.1182\/bloodadvances.2022008615"},{"key":"13","unstructured":"13 Swerdlow SH, Campo E, Harris NL, et al.,                    eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th                    Edition, Lyon, IARC Press. 2008."},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Cheson                            BD,                                Pfistner                            B,                                Juweid                            ME                    <i>et al.<\/i> Revised response criteria for malignant lymphoma. J Clin                    Oncol. 2007; 25: 579-586.","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Ogura                            M,                                Ishida                            T,                                Hatake                            K                    <i>et al.<\/i> Multicenter phase II study of mogamulizumab (KW-0761), a                    defucosylated anti-CC chemokine receptor 4 antibody, in patients with relapsed                    peripheral T-cell lymphoma and cutaneous T-cell lymphoma. J Clin Oncol. 2014;                    32: 1157-1163.","DOI":"10.1200\/JCO.2013.52.0924"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Maruyama                            D,                                Tsukasaki                            K,                                Uchida                            T                    <i>et al.<\/i> Multicenter phase 1\/2 study of forodesine in patients                    with relapsed peripheral T cell lymphoma. Ann Hematol. 2019; 98:                    131-142.","DOI":"10.1007\/s00277-018-3418-2"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Maruyama                            D,                                Nagai                            H,                                Maeda                            Y                    <i>et al.<\/i> Phase I\/ II study of pralatrexate in Japanese patients                    with relapsed or refractory peripheral T\u2010cell lymphoma. Cancer Sci. 2017; 108:                    2061-2068.","DOI":"10.1111\/cas.13340"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Maruyama                            D,                                Tobinai                            K,                                Ogura                            M                    <i>et al.<\/i> Romidepsin in Japanese patients with relapsed or                    refractory peripheral T-cell lymphoma: a phase I\/II and pharmacokinetics study.                    Int J Hematol. 2017; 106: 655-665.","DOI":"10.1007\/s12185-017-2286-1"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Kawai                            H,                                Ando                            K,                                Maruyama                            D                    <i>et al.<\/i> Phase II study of E7777 in Japanese patients with                    relapsed\/refractory peripheral and cutaneous T\u2010cell lymphoma. Cancer Sci. 2021;                    112: 2426-2435.","DOI":"10.1111\/cas.14906"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Rai                            S,                                Kim                            WS,                                Ando                            K                    <i>et al.<\/i> Oral HDAC inhibitor tucidinostat in patients with                    relapsed or refractory peripheral T-cell lymphoma: phase IIb results.                    Haematologica. 2023; 108: 811-821.","DOI":"10.3324\/haematol.2022.280996"},{"key":"21","unstructured":"21 Ufelle AC, Barchowsky A. Toxic effects of                    metals. In: Klaassen CD (ed): Casarett and Doull\u2019s Toxicology: The Basic Science                    of Poisons. 9th Edition, New York, McGraw-Hill Education. 2019; pp.                    1107-1161."},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Mochizuki                            H. Arsenic                    neurotoxicity in humans. Int J Mol Sci. 2019; 20: 3418.","DOI":"10.3390\/ijms20143418"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Tyler                            CR,                                Allan                            AM. The effects                    of arsenic exposure on neurological and cognitive dysfunction in human and                    rodent studies: a review. Curr Environ Health Rep. 2014; 1:                    132-147.","DOI":"10.1007\/s40572-014-0012-1"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Tsimberidou                            AM,                                Camacho                            LH,                                Verstovsek                            S                    <i>et al.<\/i> A phase I clinical trial of darinaparsin in patients                    with refractory solid tumors. Clin Cancer Res. 2009; 15:                    4769-4776.","DOI":"10.1158\/1078-0432.CCR-08-2984"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Ohnishi                            K,                                Yoshida                            H,                                Shigeno                            K                    <i>et al.<\/i> Arsenic trioxide therapy for relapsed or refractory                    Japanese patients with acute promyelocytic leukemia: need for careful                    electrocardiogram monitoring. Leukemia. 2002; 16: 617-622.","DOI":"10.1038\/sj.leu.2402426"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Ogura                            M,                                Kim                            WS,                                Uchida                            T                    <i>et al.<\/i> Phase I studies of darinaparsin in patients with                    relapsed or refractory peripheral T-cell lymphoma: a pooled analysis of two                    phase I studies conducted in Japan and Korea. Jpn J Clin Oncol. 2021; 51:                    218-227.","DOI":"10.1093\/jjco\/hyaa177"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/63\/2\/63_23005\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T05:11:32Z","timestamp":1688188292000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/63\/2\/63_23005\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.23005","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023]]},"article-number":"23005"}}